Karl‐Heinz Thierauch

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNFα

Nicholas Topley, Achim Jörres, Werner Luttmann et al. · Kidney International · 1993 · 254 citations

Life Sciences, Cell Biology, Immunology +9

<scp>BAY</scp> 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I

Peter Ellinghaus, Iring Heisler, Kerstin Unterschemmann et al. · Cancer Medicine · 2013 · 226 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Roberta Schmieder, Jens Hoffmann, Michael W. Becker et al. · International Journal of Cancer · 2013 · 138 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential gene expression by endothelial cells in distinct angiogenic states

Jens Glienke, Armin O. Schmitt, Christian Pilarsky et al. · European Journal of Biochemistry · 2000 · 137 citations

Life Sciences, Cell Biology, Molecular Biology +14